Tilbake til søkeresultatene

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering

Exploitation of extracellular vesicles for precision diagnostics of prostate cancer.

Alternativ tittel: Bruk av ekstracellulære vesikler for diagnostisering av prostatakreft.

Tildelt: kr 2,7 mill.

Prostatakreft er den vanligste krefttypen hos menn i Europa, med ca. 400 000 tilfeller årlig. Å utvikle sensitive ikke-invasive biomarkører for å skille mellom indolent og aggressiv prostatakreft er et viktig klinisk behov ved behandling av prostatakreft. PROSCANEXO er basert på hypotesen om at ekstracellulære vesikler i biovæsker kan brukes i prostatakreftdiagnose. PROSCANEXO vil utvikle en ultrasensitiv biosensor for kvantifisering av ekstracellulære vesikler på en rask og rimelig måte. Videre vil implementeringen av RNA-biomarkører og kartlegging av proteinkinase-aktivitet styrke spesifisiteten til de integrerte biomarkørpanelene. Biomarkørene forventes å forhindre unødvendige diagnostiske biopsier og redusere biopsier i pasientene som går på aktiv overvåking. PROSCANEXO vil derfor ha stor innvirkning på prostatakreftpasienter, helsetjenester og samfunn.

The project has identified a new miRNA signature that supports decision of active surveillance in prostate cancer patients. The project has also actively promoted the use of urine and urinary extracellular vesicles for prostate cancer diagnosis considering the close anatomical proximity of the prostate and the urethra. The project has also summarized work on the use of urinary extracellular vesicles for prostate cancer detection during the last decade and also on the use of nanotechnology for the establishment of diagnostics tests.

Prostate cancer (PCa) is the most common male cancer in Europe, where it affects approximately 400,000 men annually. The development of sensitive and versatile non-invasive biomarker assays for differentiating between benign, indolent PCa and fast progressing PCa requiring aggressive treatment, represents a great unmet clinical need in the management of PCa. PROSCANEXO is based on the hypothesis that the extracellular vesicles (EVs) count and in particular specific PCa-derived EV subpopulations are increased in biofluids of PCa patients, and that their RNA and protein content is specifically changed. EV quantification and molecular profiling can therefore be used for early PCa detection, monitoring the disease and distinguishing aggressive from indolent PCa. The overall aim of PROSCANEXO is to establish technically and clinically validated non-invasive tools for PCa diagnosis and prognosis based on the analysis of EV counts and molecular cargo in patients' biofluids. The employment of an ultrasensitive biosensor for the quantification of EVs will enable unbiased, rapid and inexpensive quantification of PCa-derived EVs and monitoring of EV dynamics during the course of the disease. The implementation of RNA biomarkers and protein kinase activity profiling will strengthen the specificity of the integrated biomarker panels. The biomarker panel is expected to prevent unnecessary diagnostic biopsies and reduce monitoring biopsies in active surveillance. PROSCANEXO will therefore have a high impact for PCa patients, the health services and society.

Budsjettformål:

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering